生物技术公司Beam Therapeutics(BEAM)11月5日股价大跌17.69%,主要原因是其基于CRISPR技术的细胞疗法BEAM-101早期临床试验中发生一名镰状细胞病患者死亡事故。
据报道,该名患者死于呼吸衰竭,很可能与为患者BEAM-101细胞输注做准备时使用的"busulfan"化疗调理药物有关。患者在输注BEAM-101治疗约四个月后不幸去世。
尽管这一事件极为不幸,但也凸显了当前临床试验方案和预处理方案仍需进一步改进以减少不良反应风险。公司目前已有8名患者接受了BEAM-101治疗。Beam Therapeutics第三季度净亏损9670万美元,同比去年略有增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.